Biologics

From Academic Foundations to Applied Intelligence: Dr. Murali Addepalli’s Journey in Advancing Biologics

1 Comment / Biologics, Health and Wellness, Health Tech, Interview, Pharma /

From Academic Foundations to Applied Intelligence: Dr. Murali Addepalli’s Journey in Advancing Biologics Toward Patient CareWork across NIH research, industry biologics programs, and emerging AI applications in drug discovery.   Most researchers dream of discovering breakthrough therapies. Dr. Murali Addepalli set himself a different, more audacious goal: actually, getting one to patients. Not publishing elegant papers about potential therapeutics that remain trapped in […]

From Academic Foundations to Applied Intelligence: Dr. Murali Addepalli’s Journey in Advancing Biologics Read More »

The Engineer Who Mastered Biology: Dr. Abhishek Mathur on Building Biologics That Patients Can Actually Afford

Leave a Comment / Biologics, Health and Wellness, Pharma /

From IIT Bombay to continuous manufacturing platforms—how one leader’s 18-year journey across Amgen, Regeneron, and Indian biotech is redefining what’s possible in biologics development Most biotechnology leaders pick a lane: deep technical expertise or broad operational leadership, Big Pharma scale or biotech agility, innovator molecules or biosimilars execution. Dr. Abhishek Mathur has systematically refused to

The Engineer Who Mastered Biology: Dr. Abhishek Mathur on Building Biologics That Patients Can Actually Afford Read More »

The Industry-Academia Bridge Builder: Dr. Samir Kulkarni on Why Biosimilars Startups Need More Than Just Funding

4 Comments / Biologics /

How two decades in biologics development shaped an unconventional academic career focused on teaching students what actually happens beyond the textbook Most academics transition from university research into industry positions seeking bigger budgets, faster timelines, and commercial impact. Dr. Samir Kulkarni took the opposite path—and it wasn’t planned. After nearly 20 years in senior leadership

The Industry-Academia Bridge Builder: Dr. Samir Kulkarni on Why Biosimilars Startups Need More Than Just Funding Read More »

The ₹50,000 Crore Gold Rush: India’s Generics Giants Race to Democratise the World’s Hottest Weight-Loss Drug

Leave a Comment / Biologics /

Few moments in modern pharmaceutical history carry the democratising force of a blockbuster patent expiry, and March 2026 is shaping up to be one of the most consequential in India’s medical landscape. On 20 March, semaglutide — the GLP-1 receptor agonist powering Novo Nordisk’s Ozempic and Wegovy franchises and widely regarded as the most transformative

The ₹50,000 Crore Gold Rush: India’s Generics Giants Race to Democratise the World’s Hottest Weight-Loss Drug Read More »

East Is the New West: How Daiichi Sankyo, Astellas, and China Are Redrawing Oncology’s Map

Leave a Comment / Biologics /

A single executive appointment rarely signals a geopolitical shift. Yet when Daiichi Sankyo announced on 24 February 2026 that Dr Yuki Kondo — former Merck Japan president and architect of Keytruda’s blockbuster regional ascent — would assume its oncology Chief Marketing Officer role, the announcement carried a weight far beyond the usual C-suite reshuffle. It

East Is the New West: How Daiichi Sankyo, Astellas, and China Are Redrawing Oncology’s Map Read More »

AI Meets Biologics: How India Plans to Reinvent Itself Beyond Generic Drugs

Leave a Comment / Biologics /

What takes ten years and costs $2 billion? Until recently, developing a single new drug molecule. What now takes months and costs a fraction of that? The same process powered by artificial intelligence platforms that Hyderabad‘s Genome Valley startups are wielding to transform India from the world’s pharmacy into a genuine innovation hub. At BioAsia

AI Meets Biologics: How India Plans to Reinvent Itself Beyond Generic Drugs Read More »

India’s ₹10,000 Crore Gamble: Turning the World’s Cheapest Pill Maker Into a Biologics Powerhouse

Leave a Comment / Biologics /

Finance Minister Nirmala Sitharaman‘s February 1, 2026, Union Budget contained a declaration of pharmaceutical ambition that industry leaders are calling transformative: Biopharma Shakti, a ₹10,000 crore five-year initiative designed to vault India from its established position as the world’s generics pharmacy—commanding 20% of global volume in small-molecule drugs—toward the technically demanding and far more lucrative

India’s ₹10,000 Crore Gamble: Turning the World’s Cheapest Pill Maker Into a Biologics Powerhouse Read More »

India Just Bet ₹10,000 Crore That It Can Beat the World at Making Biologic Drugs

Leave a Comment / Biologics /

Finance Minister Nirmala Sitharaman‘s February 1, 2026, Union Budget delivered what pharmaceutical industry leaders are already calling a “defining moment”—Biopharma Shakti, a ₹10,000 crore five-year initiative designed to catapult India from its comfortable position as the world’s generics pharmacy commanding 20% global volume toward the far more lucrative and technically demanding frontier of biologics and

India Just Bet ₹10,000 Crore That It Can Beat the World at Making Biologic Drugs Read More »

How Biologics Slashed Asthma Hospitalisations by 85% in Disadvantaged Children

Leave a Comment / Biologics, Pharma /

A Black child living in a high-deprivation neighbourhood with severe asthma faces a brutal arithmetic: twice the hospitalisation rate, three times the emergency department visits, and a relentless cascade of oral steroids that stunts growth and weakens bones whilst barely controlling symptoms. For families navigating poverty, inadequate housing, and limited healthcare access, paediatric asthma isn’t

How Biologics Slashed Asthma Hospitalisations by 85% in Disadvantaged Children Read More »

The 5.5mL Breakthrough: How Two Giants Solved Biologics’ Injection Problem

Leave a Comment / Biologics, Pharma /

Imagine requiring a life-saving cancer immunotherapy, autoimmune treatment, or obesity medication that demands injecting 5 millilitres of thick, viscous liquid through a needle at home—liquid so concentrated it flows like honey, taking minutes of sustained pressure to deliver whilst you hold perfectly still. This isn’t a hypothetical nightmare; it’s the rapidly approaching reality for millions

The 5.5mL Breakthrough: How Two Giants Solved Biologics’ Injection Problem Read More »

Scroll to Top